Combining CD40 Agonist Mitazalimab With mFOLFIRINOX for Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
Lancet Oncol 2024 May 31;[EPub Ahead of Print], JL Van Laethem, I Borbath, H Prenen, KP Geboes, A Lambert, E Mitry, PA Cassier, JF Blanc, L Pilla, JF Batlle, MR Garrote, RA Pazo-Cid, I Gallego, KE Smith, P Ellmark, Y Pico de Coaña, SV Ambarkhane, T MacarullaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.